Search Within

Michael Scordo

Formats
  1. Meeting Abstract (250)
  2. Journal Article (104)
  3. Research Letter (15)
  4. Correspondence (7)
  5. Editorial (5)
  6. Review (4)
  7. Book Section (1)
  8. Guidelines (1)
Groups
  1. Bone Marrow Transplant (387)
  2. CTCR Scholars (387)
  3. Center for Hematologic Malignancies (387)
  4. Department of Medicine (387)
  5. Hematologic Malignancies, Division of (387)
  6. Survivorship Research (338)

More Groups

People
  1. Gunjan Shah (298)
  2. Sergio Giralt (278)
  3. Miguel-Angel Perales (177)
  4. Sean Devlin (152)
  5. Heather Landau (141)
  6. Parastoo Dahi (140)

More People

Years
  1. 2025 (22)
  2. 2024 (72)
  3. 2023 (81)
  4. 2022 (49)
  5. 2021 (27)
  6. 2020 (53)

More Years

Publications
  1. Blood (123)
  2. Biology of Blood and Marrow Transplantation (56)
  3. Clinical Lymphoma, Myeloma and Leukemia (36)
  4. Bone Marrow Transplantation (26)
  5. Blood Advances (21)
  6. Transplantation and Cellular Therapy (15)

More Publications

Publishers
  1. American Society of Hematology (144)
  2. Elsevier Inc. (122)
  3. Nature Publishing Group (40)
  4. American Society of Clinical Oncology (14)
  5. Wiley Blackwell (9)
  6. Oxford University Press (7)

More Publishers

Results (387)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The association of consolidation strategies with cerebral atrophy in primary central nervous system lymphoma (PCNSL)
    Meeting Abstract

    Tringale, K. R.; Grommes, C.; Ucpinar, B. A.; Reiner, A.; Yahalom, J.; Cederquist, G.; Schaff, L.; Young, R. J.; Hatzoglou, V.; Payinkay, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Patterns of intracranial response and relapse after radiotherapy for patients with chemorefractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K. R.; Hajj, C.; Moore, Z. R.; Hubbeling, H. G.; Dreyfuss, A.; Fregonese, B.; Falchi, L.; Scordo, M.; Grommes, C.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • The promises and potential pitfalls of pharmacokinetic model–based dosing in cellular therapy
    Correspondence

    Scordo, M.
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Model-based dosing for better survival after transplantation
    Editorial

    Boelens, J. J.; Scordo, M.
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save